A 66-year-old female presented with a 1-month history of dyspepsia. An initial upper gastrointestinal endoscopy with biopsy revealed a low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. A rapid urease test was positive for Helicobacter pylori. Endoscopic ultrasound (EUS) and computed tomography (CT) revealed a 30×15-mm lymph node (LN) in the subcarinal area. Histopathologic and phenotypic analyses of the biopsy specimens obtained by EUS-guided fine-needle aspiration revealed a MALT lymphoma, and the patient was diagnosed with a stage 4E gastric MALT lymphoma. One year after H. pylori eradication, the lesion had disappeared, as demonstrated by endoscopy with biopsy, CT, fusion whole-body positron emission tomography, and EUS. Here, we describe a patient with gastric MALT lymphoma that metastasized to the mediastinal LN and regressed following H. pylori eradication. (Gut Liver 2012;6:270-274)

Key Words: Marginal zone B-cell lymphoma; Stomach

INTRODUCTION

The most common primary lymphoma of the gastrointestinal (GI) tract is mucosa-associated lymphoid tissue (MALT) lymphoma. Although 90% of gastric MALT lymphomas are related to the presence of Helicobacter pylori, areas other than the GI tract may be affected. We describe here a patient with gastric MALT lymphoma that metastasized to the mediastinal lymph node (LN) and regressed following H. pylori eradication.
and pantoprazole 80 mg a day.

An endoscopy performed 2 months after treatment showed that the gastric high and low bodies were pale and flat, with no evidence of lymphoma infiltration (Fig. 2A and C). EUS of the subcarinal area and CT showed that the LN had decreased markedly in size, to 12×11 mm (Fig. 2E and G). Follow-up PET showed no significantly abnormal hypermetabolic lesions (Fig. 2I).

One year after treatment, all assessments, including endoscopy with biopsy, CT, PET, and EUS, showed normal results (Fig. 2B, D, F, H and J). At present, 14 months later, the patient remains in complete remission.

**DISCUSSION**

More than 90% of gastric lymphomas are related to the presence of *H. pylori*; hence, eradication of *H. pylori* is the favored initial treatment for patients with early-stage *H. pylori*-positive gastric MALT lymphoma. However, the association between extragastric MALT lymphoma and *H. pylori* is not clear. Although several case reports have described the regression of extragastric MALT lymphomas after *H. pylori* eradication, one study showed that the majority of patients with extragastric MALT lymphoma did not benefit from *H. pylori* eradication.

In addition, there have been a few case reports showing that *H. pylori* eradication has led to the regression of advanced gastric MALT lymphomas simultaneously involving two or more organs other than the stomach. Recirculation of *H. pylori* - specific T-cells from the stomach to other organs via the blood or lymphatic system may trigger an inflammatory response in other MALT-lymphoma containing organs. Alternatively, abnormal cells may spread from the stomach to other organs via the blood or lymphatic system.

*H. pylori* eradication may also lead to the regression of secondarily involved perigastric LN and bone marrow. However, our patient was different, in that *H. pylori* eradication led to the regression of a mediastinal LN.
The treatment for advanced gastric MALT lymphoma has not been clearly defined. Treatment is usually similar to that for patients with other advanced-stage indolent non-Hodgkin lymphoma. Our findings, however, indicate that *H. pylori* eradication should be the first treatment in patients presenting with *H. pylori*-associated advanced gastric MALT lymphoma. Further molecular characterization of these tumors is necessary to determine the most suitable therapeutic strategy.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was declared.

---

**Fig. 2.** Follow-up evaluations 2 months (A, C, E, G, I) and 1 year (B, D, F, H, J) after *Helicobacter pylori* eradication. (A, C) Upper gastrointestinal endoscopy, displaying pale, flat gastric high and low bodies without lymphoma infiltration (H&E stain, ×400). (E, G) Endoscopic ultrasound and computed tomography scans of the subcarinal area, displaying a markedly smaller lymph node, sized 12×11 mm. (I) Positron emission tomography analysis displaying no significantly abnormal hypermetabolic lesions. (B, D, F, H, J) All findings were unremarkable.
REFERENCES

1. Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991;101:1159-1170.

2. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577.

3. Iwai H, Nakamichi N, Nakae K, et al. Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication. Laryngoscope 2009;119:1491-1494.

4. Nagashima R, Takeda H, Maeda K, Ohno S, Takahashi T. Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Gastroenterology 1996;111:1674-1678.

5. Grunberger B, Wohrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006;24:1370-1375.

6. Caletti G, Togliani T, Fusaroli P, et al. Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-Helicobacter pylori therapy. Gastroenterology 2003;124:537-543.

7. Raderer M, Pfeffl F, Pohl G, Mannhalter C, Valencak J, Chott A. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut 2006;55:1640-1642.
8. Du MQ, Xu CF, Diss TC, et al. Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. Blood 1996;88:4445–4451.

9. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2010;8:288–334.